Key result
rHuEPO therapy is linked to ~27% higher plasma endothelin-1 levels at the end of hemodialysis.
Why the study?
The pathogenesis of recombinant human erythropoietin-induced hypertension in hemodialysis patients is uncertain, with emerging evidence of endothelial involvement.
Does rHuEPO therapy increase plasma endothelin-1 levels during hemodialysis in patients with end-stage renal disease?
Observational (n=19)
Does rHuEPO therapy increase plasma endothelin-1 levels during hemodialysis in patients with end-stage renal disease?
rHuEPO therapy in hemodialysis patients is associated with elevated plasma endothelin-1 levels, though this increase does not acutely cause arterial hypertension during the dialysis session.
Answers are grounded in this paper and cite their sources.
rHuEPO-associated endothelin-1 elevation warrants no acute prescribing change; leaves open long-term vascular risk in hemodialysis.
The correction of anemia with human recombinant erythropoietin (rHuEPO) in end stage renal disease is associated with hypertension in about one third of hemodialysis patients. The pathogenesis of the rHuEPO-induced hypertension is still uncertain, though evidence of the involvement of endothelial cells has emerged. The aim of this study was to determine plasma endothelin-1 during hemodialysis and to compare the endothelin-1 levels in hemodialysis patients with and without rHuEPO substitution. Nineteen stable patients (13 male and 6 female, mean age 62 +/- 11 years) with end stage renal disease were studied. Cuprophan dialysers (GFS 12, Gambro, Lund, Sweden) were used for hemodialysis in all cases. rHuEPO (40 U/kg s.c.) was administered to 10 patients. Blood pressure (BP; RR mmHg) and blood volume changes (deltaBV; hemoglobinometry %) were serially measured. Samples were taken before and every hour during hemodialysis. Plasma endothelin-1 was measured by ELISA (R&D Systems, Minneapolis, USA) and corrected for hemoconcentration. Endothelin-1 concentration was elevated before commencement of hemodialysis (1.16 +/- 0.36 pg/ml) when compared to healthy controls (ref. 0.3-0.9) and increased to 1.47 +/- 0.51 pg/ml by the end of the session (p<0.05). In patients under rHuEPO-substitution plasma endothelin-1 was higher when compared to patients without substitution before (1.25 +/- 0.3 vs. 1.05 +/- 0.3 pg/ml) and at the end of HD (1.62 +/- 0.5 vs. 1.28 +/- 0.3 pg/ml, p<0.05). There was no difference in BP and deltaBV between the two groups during treatment. Plasma endothelin-1 was higher in hemodialysis patients and there was a continuous rise in plasma endothelin-1 during a session. Comparison of two groups of hemodialysis patients with and without s.c. rHuEPO-replacement treatment revealed a significantly higher plasma endothelin-1 concentration in patients with s.c. rHuEPO treatment. However, the elevated endothelin-1 levels were not accompanied by arterial hypertension.
No takes yet. Share an insight, caveat, or question.
Stefanidis et al. (2001) conducted an observational in End stage renal disease on hemodialysis (n=19). Recombinant human erythropoietin (rHuEPO) vs. No rHuEPO substitution was evaluated on Plasma endothelin-1 concentration at the end of hemodialysis (pg/ml) (p=<0.05). Recombinant human erythropoietin therapy in hemodialysis patients was associated with higher plasma endothelin-1 levels at the end of dialysis.
Synapse has enriched 10 related papers. Consider them for comparative context: